Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE TM Study

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-134460

Published: 2020

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-134611

Published: 2020

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL)

Nathan H. Fowler, MD, Judith Trotman, MBChB, FRACP, FRCPA, Rebecca Auer, MRCP, FRPath, PhD, Christopher R. Flowers, MD MS, William F. Reed, MD, Elena Ivanova, PhD, Jane Huang, MD, Pier Luigi Zinzani, MD PhD

Blood (2019) 134 (Supplement_1): 5252.

https://doi.org/10.1182/blood-2019-122628

Published: 2019

Journal Articles

Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Stephen Opat, Robert Marcus, MA, FRCP, FRCPath, Craig A. Portell, MD, William Reed, MD, Chris Tankersley, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 5256.

https://doi.org/10.1182/blood-2019-122629

Published: 2019

Journal Articles

Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Emma Verner, MBBS, BMedSci,FRCPA, FRACP, Amanda Johnston, FRACP,FRCPA,MBBS,BMBS,MD, Nalini Pati, MBBS,FRACP,FRCPA, DCH, MD DNB, Eliza A Hawkes, Hui-Peng Lee, MBChB, FRACP, FRCPA, BHB, Tara Cochrane, MBBS,FRCPA,FRACP, Chan Y. Cheah, Duncan Purtill, MBBS,FRCPA,FRACP, Anoop K Enjeti, MBBS,FRCPA, FRACP,PhDMD,MRCP, Christina Brown, PhDFRACP,FRCPA,MBBS, Nicholas E. Murphy, FRCPA,MBBS,FRACP, Jennifer Curnow, MBBS, FRACP, FRCPA, PhD, Julia Carlson, Belinda Butcher, BSci, MBiostat, PhD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4094.

https://doi.org/10.1182/blood-2019-124621

Published: 2019

Journal Articles

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Constantine S. Tam, MBBS, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Stephen Opat, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Aichun Liu, MD, Anna M. Johnston, Weili Zhao, MD PhD, Fernando Roncolato, BMed, FRACP, FRCPA, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Wenyu Li, MD PhD, Ted Shih, PharmD, Xiaoping Zhang, MD MS, Ken Wu, PhD, Yuan Liu, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 1594.

https://doi.org/10.1182/blood-2019-125485

Published: 2019

Journal Articles

Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial

Brad S Kahl, MD, John M. Burke, MD, Richard van der Jagt, MD FRCPC, Julie Chang, MD, Peter Wood, Tim Hawkins, FRACP, FRCPA, David MacDonald, Judith Trotman, MBChB, FRACP, FRCPA, David Simpson, MBChB, Kathryn S. Kolibaba, MD, Samar Issa, FRACP, Doreen Hallman, Ling Chen, Ian W. Flinn, MD PhD

Blood (2017) 130 (Supplement 1): 484.

https://doi.org/10.1182/blood.V130.Suppl_1.484.484

Published: 2017

Journal Articles

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies

Gavin Cull, MB, BS, FRACP, FRCPA, Stephen Opat, FRACP, FRCPA, Judith Trotman, MBChB, FRACP, FRCPA, James Hilger, Xiaoping Zhang, Shibao Feng, PhD, Sunhee Ro, PhD, Jane Huang, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 4057.

https://doi.org/10.1182/blood.V130.Suppl_1.4057.4057

Published: 2017

Journal Articles

High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study

Constantine S. Tam, MBBS, Judith Trotman, MBChB, Stephen Opat, MD, Paula Marlton, MBBS, Gavin Cull, MBBS DM FRACP FRCPA, David Simpson, MBChB, FRACP, FRCPA, Matthew Ku, MBBS, David Ritchie, MD PhD, Emma Verner, FRACP, FRCPA, MBBS, Sumita Ratnasingam, MBBS, Mary Ann Anderson, MBBS, Peter Wood, MD FRACP, FRCPA, MBBS, Mark Kirschbaum, MD, Lai Wang, PhD, Ling Xue, Jianxin Yang, Eric Hedrick, John F Seymour, Andrew W. Roberts

Blood (2016) 128 (22): 1216.

https://doi.org/10.1182/blood.V128.22.1216.1216

Published: 2016

Journal Articles

Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study

Ajay K. Gopal, MD, Stephen J. Schuster, MD, Nathan Fowler, MD, Judith Trotman, MBChB, Georg Hess, MD, Jing-Zhou Hou, Abdulraheem Yacoub, MD, Michael Lill, MD BS, Peter Martin, MD, Umberto Vitolo, MD, Wojciech Jurczak, MD, James Morton, MBBS, BSc(MD, FRACP, FRCPA, Dzhelil Osmanov, MD, Gary J. Gartenberg, MD, Jessica Vermeulen, MD PhD, Sriram Balasubramanian, PhD, Shean-sheng Wang, PhD, Sanjay Deshpande, MD, Gilles A. Salles

Blood (2016) 128 (22): 1217.

https://doi.org/10.1182/blood.V128.22.1217.1217

Published: 2016

Journal Articles

Low Suvmax Measured on Baseline FDG-PET/CT and Elevated β2 Microglobulin Are Negative Predictors of Outcome in High Tumor Burden Follicular Lymphoma Treated By Immunochemotherapy: A Pooled Analysis of Three Prospective Studies

Anne Ségolène Cottereau, MD, Annibale Versari, MD, Loïc Chartier, Jehan Dupuis, MD, Vittoria Tarantino, MD, Rene-Olivier Casasnovas, MD, Antonella Franceschetto, Emmanuel Itti, MD PhD, Hervé Tilly, MD PhD, Corinne Haioun, MD, Massimo Federico, MD PhD, Alina Berriolo, MD, Gilles Andre Salles, MD PhD, Stefano Luminari, Michel Meignan, MD PhD, Judith Trotman, MBChB

Blood (2016) 128 (22): 1101.

https://doi.org/10.1182/blood.V128.22.1101.1101

Published: 2016

Journal Articles

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Constantine S. Tam, MBBS, Stephen Opat, MD, Gavin Cull, MBBS DM FRACP FRCPA, Judith Trotman, MBChB, David Gottlieb, MBBS MD FRACP FRCPA, David Simpson, MBChB, FRACP, FRCPA, Paula Marlton, MBBS, Mary Ann Anderson, MBBS, Matthew Ku, MBBS, David Ritchie, MD PhD, Sumita Ratnasingam, MBBS, Bradley Augustson, Mark Kirschbaum, MD, Lai Wang, PhD, Ling Xue, Jianxin Yang, Eric Hedrick, John F Seymour, Andrew W. Roberts

Blood (2016) 128 (22): 642.

https://doi.org/10.1182/blood.V128.22.642.642

Published: 2016

Journal Articles

First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa

Blood (2016) 128 (22): 471.

https://doi.org/10.1182/blood.V128.22.471.471

Published: 2016

Journal Articles

Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor Burden Follicular Lymphoma. A Pooled Analysis of Three Multicenter Studies

Michel Meignan, Annibale Versari, MD, Anne Ségolène Cottereau, Loïc Chartier, Jehan Dupuis, MD, Sami Boussetta, Ilaria Grassi, Rene-Olivier Casasnovas, MD, Corinne Haioun, MD PhD, Hervé Tilly, MD PhD, Massimo Federico, Gilles A. Salles, MD PhD, Stefano Luminari, MD, Judith Trotman, MBChB

Blood (2015) 126 (23): 3919.

https://doi.org/10.1182/blood.V126.23.3919.3919

Published: 2015

Journal Articles

Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG)

Blood (2015) 126 (23): 815.

https://doi.org/10.1182/blood.V126.23.815.815

Published: 2015

Journal Articles

Evaluation of Pharmacokinetic-Based Dose Predictions of High Dose Melphalan in Patients with Myeloma

Judith Trotman, MBChB, Peter J. Shaw, MBBS, MA, FRACP, Campbell Tiley, MBBS,FRACP, FRCPA, Sundra Ramanathan, MBBS FRCPA FRACP, Andrew P Grigg, MBBS MD, Stephen Robert Larsen, MBBS PhDFRCPA FRACP, Peter Presgrave, MBBS, PhD FRACP, FRCPA, Yiu-Lam Kwan, MBBS, FRACP, FRCPA, Elizabeth Newman, RN, Christa Nath, BSC (Hons), PhD

Blood (2015) 126 (23): 4314.

https://doi.org/10.1182/blood.V126.23.4314.4314

Published: 2015

Journal Articles

Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials

Hang Quach, MD, Simon Harrison, MD, Liam J. Fernyhough, MB, BS, BMedSci, Ross Alistair Henderson, PhD FRACP, FRCPA, Gillian Corbett, MDFRACP FRCPA, Peter Browett, MBChB, FRACP, FRCPA, Hilary Anne Blacklock, FRACP, Craig Underhill, MD, Paul Cannell, MD, Judith Trotman, MBChB, Emma Link, Linda Cowan, Jack S Li, Meletios A. Dimopoulos, H. Miles Prince, MD

Blood (2015) 126 (23): 4236.

https://doi.org/10.1182/blood.V126.23.4236.4236

Published: 2015

Journal Articles

First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

Blood (2015) 126 (23): 341.

https://doi.org/10.1182/blood.V126.23.341.341

Published: 2015

Journal Articles

Increasing Cross-Referral and Recruitment to Clinical Trials: A New Approach

Roslyn Ristuccia, BSc MMedSc, Xavier C Badoux, MBBS, Melinda Gibson, BAppS MHSc, Admir Huseincehajic, BSc, Judith Trotman, MBChB

Blood (2015) 126 (23): 636.

https://doi.org/10.1182/blood.V126.23.636.636

Published: 2015

NARROW

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE TM Study

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL)

Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies

High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study

Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study

Low Suvmax Measured on Baseline FDG-PET/CT and Elevated β2 Microglobulin Are Negative Predictors of Outcome in High Tumor Burden Follicular Lymphoma Treated By Immunochemotherapy: A Pooled Analysis of Three Prospective Studies

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa

Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor Burden Follicular Lymphoma. A Pooled Analysis of Three Multicenter Studies

Evaluation of Pharmacokinetic-Based Dose Predictions of High Dose Melphalan in Patients with Myeloma

Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials

First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

Increasing Cross-Referral and Recruitment to Clinical Trials: A New Approach

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only